Denosumab for Giant Cell Tumor of Bone: Off-Label Prolia vs. FDA-Approved Xgeva

Why the Prolia vs. Xgeva Distinction Matters

Denosumab is a single molecule sold under two brand names at vastly different doses for different diseases. Confusing Prolia with Xgeva in the GCTB setting can lead to severe underdosing. The FDA approved Xgeva (denosumab 120 mg subcutaneously every 4 weeks, with loading doses on days 8 and 15 of month one) for giant cell tumor of bone in June 2013 [1]. Prolia (denosumab 60 mg subcutaneously every 6 months) carries indications only for postmenopausal osteoporosis, glucocorticoid-induced osteoporosis, and bone loss in patients on androgen deprivation or aromatase inhibitor therapy [2].

A patient receiving Prolia for GCTB would get roughly 10 mg per month. A patient on the correct Xgeva regimen gets 120 mg per month after the loading phase. That is a 12-fold difference in monthly exposure. The Institute for Safe Medication Practices (ISMP) has flagged Prolia/Xgeva mix-ups as a recurring safety signal [3]. Any search for "Prolia for giant cell tumor" should end at this fact: the molecule works, but the formulation and dose must be Xgeva.

How Denosumab Works Against Giant Cell Tumors

GCTB is a locally aggressive, rarely metastatic bone neoplasm driven by osteoclast-like giant cells that express high levels of receptor activator of nuclear factor kappa-B ligand (RANKL). Denosumab binds RANKL with high affinity, preventing it from activating the RANK receptor on osteoclast precursors [4]. Without this signal, the multinucleated giant cells cannot form and existing giant cells undergo apoptosis.

The result is measurable within weeks. Histologic analysis of resected specimens after neoadjuvant denosumab shows near-complete elimination of giant cells and replacement of lytic bone with dense woven bone [5]. This dual effect (tumor cell death plus new bone formation in the defect) is what makes denosumab uniquely suited for GCTB. No chemotherapy agent achieves this combination. Bisphosphonates share some anti-osteoclast activity but lack the potency and specificity of direct RANKL inhibition.

Clinical Evidence: The Phase II Trials

The key evidence for denosumab in GCTB comes from two open-label phase II studies conducted by Amgen (Studies 20040215 and 20062004) that collectively enrolled over 500 patients [6].

Study 20040215 (Thomas et al., 2010)

This trial enrolled 37 patients with recurrent or unresectable GCTB. At a median follow-up of 9.2 months, 30 of 35 evaluable patients (86%) had a tumor response defined by elimination of giant cells on histology or lack of radiographic progression [7]. No patients showed disease progression while on denosumab. The safety profile was consistent with the known effects of RANKL inhibition.

Study 20062004 (Chawla et al., 2019)

The larger, confirmatory study enrolled 532 patients across three cohorts: surgically unsalvageable GCTB, salvageable GCTB where planned surgery would cause significant morbidity, and a rollover cohort. Among patients in cohort 2, 163 of 238 (68%) were downstaged enough to undergo less morbid surgery or avoid surgery entirely. The objective response rate by inverse Choi criteria was 72% in cohort 1 and 76% in cohort 2 [8]. Median time on treatment was 14.4 months.

These are single-arm studies without placebo comparators, a fact that limits the strength of the evidence to GRADE level "moderate." A randomized trial against surgery alone was considered unethical given the morbidity of en bloc resection for axial and periarticular GCTB.

FDA-Approved Dosing and Administration

The approved Xgeva regimen for GCTB is specific and aggressive compared to the osteoporosis dose [1]:

• 120 mg subcutaneously on day 1, day 8, and day 15 of the first month (loading phase)
• 120 mg subcutaneously every 4 weeks thereafter
• Supplementation with calcium (at least 500 mg daily) and vitamin D (at least 400 IU daily) unless hypercalcemia is present

Treatment continues until either the tumor becomes resectable and surgery is performed, or indefinitely in unresectable cases. There is no FDA-recommended maximum duration. The prescribing information does not address a stopping protocol, which is itself a clinical problem (discussed below).

Risks and Adverse Events

Denosumab at oncologic doses carries a higher adverse-event burden than the osteoporosis dose. The risks fall into several categories.

Osteonecrosis of the Jaw (ONJ)

In the GCTB trials, ONJ occurred in approximately 1% to 5% of patients, with risk increasing after 12 months of exposure [8]. The American Association of Oral and Maxillofacial Surgeons recommends a dental examination with preventive dentistry before starting denosumab and avoidance of invasive dental procedures during treatment [9]. Patients should be counseled that jaw pain, exposed bone, or non-healing extraction sockets require urgent evaluation.

Hypocalcemia

Denosumab suppresses bone resorption, which reduces calcium release from the skeleton. In the GCTB population (younger, generally calcium-replete), clinically significant hypocalcemia is uncommon (<3%) but can be severe when it occurs. Patients with vitamin D deficiency or renal impairment are at highest risk [1]. Serum calcium should be checked within 2 weeks of the first dose and periodically thereafter.

Atypical Femoral Fracture

Long-term RANKL inhibition (typically beyond 3 to 5 years) has been associated with atypical subtrochanteric and diaphyseal femoral fractures in osteoporosis populations [10]. The absolute risk in GCTB patients receiving higher doses for shorter durations is less well characterized, but any patient reporting thigh or groin pain during treatment should be evaluated with full-length femoral imaging.

Rebound Hypercalcemia and Osteolysis After Discontinuation

This is the most clinically consequential risk specific to the GCTB setting. When denosumab is stopped, RANKL signaling rebounds. In osteoporosis patients, this manifests as rapid bone loss and vertebral fractures. In GCTB patients, the rebound can reactivate dormant tumor cells.

A 2019 retrospective analysis by Palmerini et al. found that 62% of patients who discontinued denosumab after neoadjuvant treatment experienced local recurrence, compared to 28% who continued treatment [11]. Rebound hypercalcemia has also been reported in isolated cases, requiring monitoring of serum calcium for at least 6 months after the last dose [12].

The Discontinuation Problem

No randomized data define the optimal strategy for stopping denosumab in GCTB. Three approaches appear in the literature:

Indefinite treatment. Continuing Xgeva every 4 weeks prevents recurrence but exposes patients to cumulative ONJ risk and the financial burden of a biologic agent indefinitely. Given that GCTB predominantly affects patients aged 20 to 40, this could mean decades of treatment [6].

Transition to bisphosphonates. Some centers administer one or two infusions of zoledronic acid (5 mg IV) after the last denosumab dose to blunt the rebound in bone turnover. This approach is extrapolated from the osteoporosis discontinuation literature and has not been validated in a GCTB-specific trial [13]. A 2022 single-center retrospective from the Rizzoli Institute reported a lower recurrence rate (18%) in patients who received transition bisphosphonates versus those who stopped abruptly (39%), but the sample size was 67 patients and selection bias is likely [14].

Neoadjuvant treatment followed by curettage. Giving denosumab for 3 to 6 months to induce ossification of the tumor, then performing intralesional curettage with adjuvant cement or bone graft, provides a definitive surgical margin while limiting denosumab exposure. Recurrence rates after this strategy range from 15% to 40% depending on tumor site and completeness of curettage [15]. This is the most common approach for resectable GCTB.

The lack of a clear stopping rule is the single largest gap in the GCTB/denosumab evidence base. The European Society for Medical Oncology (ESMO) clinical practice guidelines recommend discussing discontinuation strategy before initiating treatment [16].

When Denosumab Is Preferred Over Surgery Alone

Not every GCTB requires denosumab. Small, accessible, expendable-bone tumors (such as those in the distal ulna or proximal fibula) can be treated with en bloc resection alone, with recurrence rates below 10%. Denosumab adds the most value in three scenarios.

Axial skeleton and sacral GCTB. Sacral GCTB is notoriously difficult to resect without damaging nerve roots controlling bowel, bladder, and sexual function. Denosumab can control disease without surgery in many of these patients. In the Chawla et al. cohort, 74% of sacral GCTB patients avoided surgery entirely [8].

Periarticular GCTB threatening joint preservation. GCTB around the knee (distal femur, proximal tibia) accounts for roughly 50% of cases. Without neoadjuvant denosumab, extensive curettage or resection may require endoprosthetic reconstruction. Preoperative denosumab consolidates the tumor margin with new bone, allowing joint-sparing curettage [15].

Metastatic GCTB. Pulmonary metastases occur in 2% to 5% of GCTB cases. These are typically indolent and may respond to denosumab, though data are limited to case series [6].

Monitoring During Treatment

Patients receiving Xgeva for GCTB require a structured monitoring protocol. Serum calcium and phosphorus should be checked at baseline, 2 weeks after first dose, and every 3 months thereafter. 25-hydroxyvitamin D should be repleted to at least 30 ng/mL before starting treatment. Dental evaluation is required before initiation and every 6 months during treatment [1].

Imaging follow-up typically uses MRI every 3 to 6 months, assessing for changes in tumor signal, peripheral ossification, and soft-tissue extent. CT is useful for evaluating the quality of new bone formation within the tumor. Standard RECIST criteria do not apply well to GCTB because the tumor may not shrink in diameter but instead ossifies and becomes quiescent. Modified response criteria, such as inverse Choi criteria or the Campanacci radiographic grading system, are preferred [8].

Comparing Denosumab to Other GCTB Treatments

Before denosumab, treatment options for unresectable GCTB were limited. Interferon-alpha showed modest responses in small series. Bisphosphonates (primarily zoledronic acid) produced partial responses in roughly 30% of patients in a small prospective study, far below the 72% to 86% response rates seen with denosumab [17]. Serial arterial embolization has a role in sacral GCTB but is palliative rather than disease-modifying. Radiation therapy is generally avoided because of the risk of malignant transformation (secondary sarcoma in 2% to 10% of irradiated GCTB) [6].

Denosumab occupies a unique position: it is the only systemic therapy with demonstrated high response rates in GCTB, but it is not curative. The tumor biology persists, and recurrence after discontinuation is the expected outcome unless surgery removes all viable tumor tissue.

Special Populations and Considerations

Pregnancy

Denosumab is contraindicated in pregnancy (Category X equivalent under the prior FDA system). RANKL inhibition disrupts fetal bone and tooth development in animal models. Women of reproductive age must use effective contraception during treatment and for at least 5 months after the last dose [1]. Because GCTB peaks in the 20-to-40 age group, this is a frequent practical concern.

Pediatric Patients

Xgeva is approved for skeletally mature adolescents (aged 13 and older) with GCTB based on a subset of patients in the phase II trials. In skeletally immature patients, RANKL inhibition can impair longitudinal bone growth, and use is not recommended [1].

Renal Impairment

No dose adjustment is required for renal impairment because denosumab is cleared by the reticuloendothelial system, not the kidneys. Hypocalcemia risk is elevated in severe renal impairment (creatinine clearance <30 mL/min), and these patients require closer monitoring [1].

Cost and Access

Xgeva carries a wholesale acquisition cost of approximately $1,900 per 120 mg injection in the United States, translating to roughly $24,700 per year at the standard Q4-week schedule (excluding loading doses) [18]. Most commercial insurers and Medicare Part B cover Xgeva for the FDA-approved GCTB indication under a buy-and-bill model. Prolia, at approximately $1,200 per injection every 6 months, is dramatically cheaper but provides the wrong dose for GCTB. Prescribing Prolia to save cost in a GCTB patient is a medication error, not a cost-saving strategy.

Amgen offers the Amgen Safety Net Foundation for uninsured or underinsured patients, and specialty pharmacies can assist with prior authorization for the GCTB indication since it is on-label for Xgeva [18].

The recurrence rate with denosumab for GCTB after curettage ranges from 15% to 40% depending on tumor site, and clinicians should discuss both surgical timing and a bisphosphonate transition strategy before the first Xgeva injection [15].